Notice2022-07575
Foreign-Trade Zone (FTZ) 61-San Juan, Puerto Rico Notification of Proposed Production Activity, AIAC International Pharma, LLC (Pharmaceutical Products), Arecibo, Puerto Rico
Primary source
Metadata and text below are from the Federal Register, a public-domain U.S. government work. Always verify the official published version before relying on it for any legal matter.
Published
April 8, 2022
Issuing agencies
Commerce DepartmentForeign-Trade Zones Board
Full Text
<html>
<head>
<title>Federal Register, Volume 87 Issue 68 (Friday, April 8, 2022)</title>
</head>
<body><pre>
[Federal Register Volume 87, Number 68 (Friday, April 8, 2022)]
[Notices]
[Pages 20813-20814]
From the Federal Register Online via the Government Publishing Office [<a href="http://www.gpo.gov">www.gpo.gov</a>]
[FR Doc No: 2022-07575]
=======================================================================
-----------------------------------------------------------------------
DEPARTMENT OF COMMERCE
Foreign-Trade Zones Board
[B-11-2022]
Foreign-Trade Zone (FTZ) 61--San Juan, Puerto Rico Notification
of Proposed Production Activity, AIAC International Pharma, LLC
(Pharmaceutical Products), Arecibo, Puerto Rico
The Department of Economic Development and Commerce, grantee of
[[Page 20814]]
FTZ 61, submitted a notification of proposed production activity to the
FTZ Board (the Board) on behalf of AIAC International Pharma, LLC,
located in Arecibo, Puerto Rico within Subzone 61D. The notification
conforming to the requirements of the Board's regulations (15 CFR
400.22) was received on April 1, 2022.
Pursuant to 15 CFR 400.14(b), FTZ production activity would be
limited to the specific foreign-status material and specific finished
product described in the submitted notification (summarized below) and
subsequently authorized by the Board. The benefits that may stem from
conducting production activity under FTZ procedures are explained in
the background section of the Board's website--accessible via
<a href="http://www.trade.gov/ftz">www.trade.gov/ftz</a>. The proposed finished product and material would be
added to the production authority that the Board previously approved
for the operation, as reflected on the Board's website.
The proposed finished product is XCOPRI (cenobamate tablets) (duty-
free).
The proposed foreign-status material is cenobamate active
pharmaceutical ingredient (duty rate 6.5%).
Public comment is invited from interested parties. Submissions
shall be addressed to the Board's Executive Secretary and sent to:
<a href="/cdn-cgi/l/email-protection#5a3c2e201a2e283b3e3f743d352c"><span class="__cf_email__" data-cfemail="5137252b1125233035347f363e27">[email protected]</span></a>. The closing period for their receipt is May 18, 2022.
A copy of the notification will be available for public inspection
in the ``Online FTZ Information System'' section of the Board's
website.
For further information, contact Christopher Wedderburn at
<a href="/cdn-cgi/l/email-protection#e5a68d978c96cbb280818180978790978ba59197848180cb828a93"><span class="__cf_email__" data-cfemail="43002b312a306d1426272726312136312d0337312227266d242c35">[email protected]</span></a>.
Dated: April 5, 2022.
Andrew McGilvray,
Executive Secretary.
[FR Doc. 2022-07575 Filed 4-7-22; 8:45 am]
BILLING CODE 3510-DS-P
</pre><script data-cfasync="false" src="/cdn-cgi/scripts/5c5dd728/cloudflare-static/email-decode.min.js"></script></body>
</html>Indexed from Federal Register on April 8, 2022.
This is legal information, not legal advice. Laws vary by jurisdiction and change frequently. Always verify current law with official sources and consult a licensed attorney in your jurisdiction for advice on your specific situation.